AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20231595 — intervention group
Group type: EXPERIMENTAL
Intervention: Desired position of the eyebrows in men
Number of subjects: 40
Study 20231595 — intervention group
Group type: EXPERIMENTAL
Intervention: Brow peak position
Number of subjects: 40
Study 20231595 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of movement of the eyebrows
Number of subjects: 40
Study 20231595 — intervention group
Group type: EXPERIMENTAL
Intervention: Aesthetic position of the medial and central brow
Number of subjects: 40
Study 20231595 — intervention group
Group type: EXPERIMENTAL
Intervention: Brow peak position recommendation
Number of subjects: 40
Study 20231595 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical planning recommendation
Number of subjects: 40
Study 20231626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization of circulating angiogenic cells (CACs)
Number of subjects: 31
Study 20231626 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn wound perfusion and vascularization
Number of subjects: 31
Study 20231626 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC levels in peripheral blood
Number of subjects: 31
Study 20233136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow cells (BMSC)
Number of subjects: 32
Study 20233403 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors associated with Road Traffic Injuries (RTI) in a driving population
Number of subjects: 1540
Study 20233444 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoCarta panel
Number of subjects: 239
Study 20233444 — intervention group
Group type: EXPERIMENTAL
Intervention: ColoCarta panel
Number of subjects: 239
Study 20233444 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation profiling of metastatic lymph nodes
Number of subjects: 239
Study 20233444 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation frequencies
Number of subjects: 239
Study 20233448 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-based marketing intervention
Number of subjects: 360
Study 20233448 — intervention group
Group type: COMPARATOR
Intervention: Usual-care marketing
Number of subjects: 360
Study 20233976 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE score <26
Number of subjects: 2510
Study 20233976 — intervention group
Group type: EXPERIMENTAL
Intervention: TTR <65%
Number of subjects: 2510
Study 20233976 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE score <24
Number of subjects: 2510
Study 20233976 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE score 24 to 25
Number of subjects: 2510
Study 20233976 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved anticoagulation
Number of subjects: 2510
Study 20234331 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-7 vaccine administered at 2, 4, and 6 months after birth
Number of subjects: 369
Study 20234331 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-7 vaccine administered
Number of subjects: 369
Study 20236340 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual migraine treatment episodes
Number of subjects: 153
Study 20236340 — intervention group
Group type: COMPARATOR
Intervention: Nonmenstrual migraine treatment episodes
Number of subjects: 153
Study 20236500 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon
Number of subjects: 0
Study 20236500 — intervention group
Group type: COMPARATOR
Intervention: Xenon
Number of subjects: 0
Study 20236700 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 100 mg
Number of subjects: 1328
Study 20236700 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg
Number of subjects: 1328
Study 20236700 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 400 mg
Number of subjects: 1328
Study 20236700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1328
Study 20236700 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 1328
Study 20236700 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 1328
Study 20236700 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 1328
Study 20236700 — intervention group
Group type: COMPARATOR
Intervention: AHU377 200 mg
Number of subjects: 1328
Study 20237039 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-assisted management (group 1)
Number of subjects: 111
Study 20237039 — intervention group
Group type: COMPARATOR
Intervention: Standard care (group 2)
Number of subjects: 111
Study 20237039 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-assisted management (group 3)
Number of subjects: 111
Study 20237039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ottawa-FIVE patients
Number of subjects: 111
Study 20237066 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K concentration in subcutaneous adipose tissue
Number of subjects: 459
Study 20237066 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K concentration in visceral adipose tissue
Number of subjects: 459
Study 20237066 — intervention group
Group type: COMPARATOR
Intervention: Plasma K(1) levels in women
Number of subjects: 459
Study 20237066 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating concentrations of uncarboxylated prothrombin in men
Number of subjects: 459
Study 20237066 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating concentrations of uncarboxylated prothrombin in women
Number of subjects: 459
Study 20237066 — intervention group
Group type: COMPARATOR
Intervention: Percentage of undercarboxylated osteocalcin
Number of subjects: 459
Study 20298558 — intervention group
Group type: EXPERIMENTAL
Intervention: Central arterial pressure and pulse wave velocity measurement
Number of subjects: 110
Study 20298563 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation intervention (letter to discuss thiazide diuretics)
Number of subjects: 54
Study 20298564 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation strategy (letters and incentives to discuss thiazides)
Number of subjects: 21
Study 20298923 — intervention group
Group type: EXPERIMENTAL
Intervention: DES overlap
Number of subjects: 1012
Study 20298926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 28
Study 20298926 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 20299029 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcoronary Ross procedure
Number of subjects: 501
Study 20299511 — intervention group
Group type: EXPERIMENTAL
Intervention: Velaglucerase alfa (60 U/kg per infusion) during phase 1/2
Number of subjects: 12
Study 20299511 — intervention group
Group type: EXPERIMENTAL
Intervention: Velaglucerase alfa (30 U/kg per infusion) during extension study
Number of subjects: 12
Study 20299634 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) measurement
Number of subjects: 925
Study 20299634 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic pretreatment
Number of subjects: 925
Study 20299634 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin serum levels
Number of subjects: 925
Study 20299957 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil in HIV-infected patients on efavirenz
Number of subjects: 0
Study 20299957 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil in HIV-infected patients on lopinavir/ritonavir
Number of subjects: 0
Study 20299957 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil in HIV-infected patients on atazanavir/ritonavir
Number of subjects: 0
Study 20299957 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Number of subjects: 0
Study 20307284 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid supplement (exact dosage not specified)
Number of subjects: 0
Study 20307284 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty acid analysis of RBCs
Number of subjects: 0
Study 20307284 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty acid analysis of WBCs
Number of subjects: 0
Study 20307398 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release alpha lipoic acid (CRLA) 600 mg twice daily for 16 weeks
Number of subjects: 6
Study 20331856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 52
Study 20331856 — intervention group
Group type: COMPARATOR
Intervention: No dobutamine
Number of subjects: 52
Study 20334673 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nicotine delivery system (Smoke-Break)
Number of subjects: 69
Study 20334992 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial compartment disease
Number of subjects: 0
Study 20334992 — intervention group
Group type: COMPARATOR
Intervention: Axial compartment disease
Number of subjects: 0
Study 20334992 — intervention group
Group type: COMPARATOR
Intervention: Superolateral compartment disease
Number of subjects: 0
Study 20335221 — intervention group
Group type: EXPERIMENTAL
Intervention: Placenta growth factor (PlGF) levels in patients with SCD
Number of subjects: 123
Study 20335221 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythroid expression of PlGF simulated in normal mice using a lentivirus vector
Number of subjects: 123
Study 20335545 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiced Burger (SB) seasoned with antioxidant spice blend
Number of subjects: 11
Study 20335545 — intervention group
Group type: COMPARATOR
Intervention: Control Burger (CB) not seasoned with spice blend
Number of subjects: 11
Study 20335545 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiced Burger (SB)
Number of subjects: 11
Study 20335583 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily
Number of subjects: 299
Study 20335583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 20338042 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial third of the tibial tuberosity as a reference for tibial rotational alignment
Number of subjects: 80
Study 20338042 — intervention group
Group type: COMPARATOR
Intervention: Medial border of the tibial tubercle as a reference for tibial rotational alignment
Number of subjects: 80
Study 20338746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy followed by low intensity 'maintenance' chemotherapy (6-drug regimen with local therapy of surgery and/or radiotherapy followed by 9 courses of vincristine, actinomycin D and cyclophosphamide (VAC)) for SRG.
Number of subjects: 146
Study 20338746 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose monotherapy followed by low dose maintenance chemotherapy (VAC) for PRG.
Number of subjects: 146
Study 20339536 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day simvastatin for 6 weeks
Number of subjects: 3932
Study 20339536 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day pravastatin for 24 weeks
Number of subjects: 3932
Study 20339536 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day atorvastatin for 8 weeks
Number of subjects: 3932
Study 20345222 — intervention group
Group type: EXPERIMENTAL
Intervention: (125)I-mAb 425 radioimmunotherapy (RIT)
Number of subjects: 192
Study 20345222 — intervention group
Group type: EXPERIMENTAL
Intervention: (125)I-mAb 425 and temozolomide (TMZ+RIT)
Number of subjects: 192
Study 20345222 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (CTL)
Number of subjects: 192
Study 20345222 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 192
Study 20345222 — intervention group
Group type: COMPARATOR
Intervention: RIT vs CTL
Number of subjects: 192
Study 20345222 — intervention group
Group type: COMPARATOR
Intervention: TMZ+RIT vs CTL
Number of subjects: 192
Study 20345222 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ+RIT vs RIT
Number of subjects: 192
Study 20346127 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol fixed combination (FC)
Number of subjects: 383
Study 20346156 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with Hope Program (LWHP)
Number of subjects: 200
Study 20346568 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral head position (mean angle -1 degrees) in pre-school children
Number of subjects: 61
Study 20346568 — intervention group
Group type: COMPARATOR
Intervention: Head-extension position (mean angle 13 degrees) in pre-school children
Number of subjects: 61
Study 20346568 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral head position (mean angle -0.4 degrees) in school children
Number of subjects: 61
Study 20346568 — intervention group
Group type: COMPARATOR
Intervention: Head-extension position (mean angle 15.7 degrees) in school children
Number of subjects: 61
Study 20346578 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal laser ablation (FLA)
Number of subjects: 4
Study 20346578 — intervention group
Group type: EXPERIMENTAL
Intervention: Postablation MRI
Number of subjects: 4
Study 20347684 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour free-living walking in a flat public park with GPS recording at 0.5 Hz
Number of subjects: 57
Study 20348194 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Number of subjects: 150
Study 20348194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EBUS-TBNA and EUS-B-FNA
Number of subjects: 150
Study 20348194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EUS-B-FNA with EBUS-TBNA
Number of subjects: 150
Study 20348198 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent group (met new LCD criteria)
Number of subjects: 150
Study 20348198 — intervention group
Group type: COMPARATOR
Intervention: Nonadherent group (failed to meet new LCD criteria)
Number of subjects: 150
Study 20348198 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not receive any special adherence intervention
Number of subjects: 150
Study 20348198 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence
Number of subjects: 150
Study 20350136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate CYP2D6 metabolism (0.5 SGD)
Number of subjects: 100
Study 20350136 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 poor metabolizers
Number of subjects: 100
Study 20350189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment during pregnancy (IPTp)
Number of subjects: 549
Study 20350190 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA
Number of subjects: 36
Study 20350190 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA (1 x 10(7) TCID(50) intradermally)
Number of subjects: 36
Study 20350190 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA (1 x 10(7) TCID(50) intramuscularly)
Number of subjects: 36
Study 20350190 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA (intradermally)
Number of subjects: 36
Study 20350192 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin derivatives treatment
Number of subjects: 0
Study 20350302 — intervention group
Group type: EXPERIMENTAL
Intervention: LY450139 (100 mg)
Number of subjects: 35
Study 20350302 — intervention group
Group type: EXPERIMENTAL
Intervention: LY450139 (140 mg)
Number of subjects: 35
Study 20350302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 20350831 — intervention group
Group type: EXPERIMENTAL
Intervention: OPA3A deficiency (as in optic atrophy type 3)
Number of subjects: 0
Study 20350831 — intervention group
Group type: EXPERIMENTAL
Intervention: Green fluorescent protein tagged OPA3 expression studies
Number of subjects: 0
Study 20350831 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of OPA3A
Number of subjects: 0
Study 20354183 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily
Number of subjects: 191
Study 20354489 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoplasty technique using the PolarCath device
Number of subjects: 100
Study 20354809 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic InterStim Therapy device (Medtronic) implantation
Number of subjects: 120
Study 20357040 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum linoleic acid (LA, 18:2n-6)
Number of subjects: 1098
Study 20357040 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum arachidonic acid (AA, 20:4n-6)
Number of subjects: 1098
Study 20357194 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral-domain optical coherence tomography (SD-OCT) and confocal scanning laser ophthalmoscopy (cSLO)
Number of subjects: 26
Study 20359362 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial venue group
Number of subjects: 321
Study 20359362 — intervention group
Group type: EXPERIMENTAL
Intervention: Public venue group
Number of subjects: 321
Study 20359362 — intervention group
Group type: COMPARATOR
Intervention: Private venue group
Number of subjects: 321
Study 20361905 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination
Number of subjects: 5
Study 20361905 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 5
Study 20361905 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 5
Study 20362695 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous liver biopsy
Number of subjects: 2740
Study 20362695 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with platelet counts of 60,000/mm(3) or less
Number of subjects: 2740
Study 20362695 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with international normalized ratio of 1.3 or greater
Number of subjects: 2740
Study 20362695 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluding subjects with platelet count of 60,000/mm(3) or less
Number of subjects: 2740
Study 20362695 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator experience, type of needle used, ultrasound guidance
Number of subjects: 2740
Study 20362695 — intervention group
Group type: EXPERIMENTAL
Intervention: Persons with hepatitis C and advanced fibrosis
Number of subjects: 2740
Study 20362723 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR systems (30% EHR-only; 22% both EHR and paper)
Number of subjects: 15381
Study 20362723 — intervention group
Group type: COMPARATOR
Intervention: Paper-only systems
Number of subjects: 15381
Study 20362723 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR systems
Number of subjects: 15381
Study 20362722 — intervention group
Group type: EXPERIMENTAL
Intervention: AED plus CPR training
Number of subjects: 7001
Study 20362722 — intervention group
Group type: COMPARATOR
Intervention: CPR training only
Number of subjects: 7001
Study 20363090 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX) 380 mg, intramuscular, with monthly medical management (MM)
Number of subjects: 72
Study 20363090 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly medical management (MM)
Number of subjects: 72
Study 20364383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraepidermal injection of autologous dissociated epidermal cell suspension
Number of subjects: 10
Study 20368313 — intervention group
Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate (GFR) reference values measured at inclusion and weekly for the first month using 12-hour urine specimens.
Number of subjects: 275
Study 20368317 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical/otologic score including symptoms and tympanic-membrane examination
Number of subjects: 469
Study 20368317 — intervention group
Group type: EXPERIMENTAL
Intervention: AOM total-severity index including symptoms and tympanic-membrane examination
Number of subjects: 469
Study 20368317 — intervention group
Group type: COMPARATOR
Intervention: AOM severity-of-symptom scale based solely on symptoms
Number of subjects: 469
Study 20368322 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with inadequate literacy
Number of subjects: 200
Study 20368322 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with adequate literacy
Number of subjects: 200
Study 20368322 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with limited literacy
Number of subjects: 200
Study 20368322 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with at least 50% correct math answers
Number of subjects: 200
Study 20368322 — intervention group
Group type: COMPARATOR
Intervention: Caregivers who failed to answer at least 50% of math questions correctly
Number of subjects: 200
Study 20368434 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (20 mg/m² i.v. over 1 h on days 1 to 10)
Number of subjects: 53
Study 20368649 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography
Number of subjects: 371
Study 20368649 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography and venography
Number of subjects: 371
Study 20368649 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography (including technically inadequate images)
Number of subjects: 371
Study 20369375 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin 500 mg/day
Number of subjects: 0
Study 20370777 — intervention group
Group type: EXPERIMENTAL
Intervention: Early progression to shock within 72 hours
Number of subjects: 472
Study 20370777 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression to severe sepsis or shock within 72 hours
Number of subjects: 472
Study 20372873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day) for 24 weeks
Number of subjects: 6
Study 20372873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day) for 48 weeks
Number of subjects: 6
Study 20372873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day) for 24 and 48 weeks
Number of subjects: 6
Study 20372873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day)
Number of subjects: 6
Study 20374273 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelated patients
Number of subjects: 44
Study 20374273 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SCD
Number of subjects: 44
Study 20374273 — intervention group
Group type: COMPARATOR
Intervention: Patients with TM
Number of subjects: 44
Study 20375178 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexcision urine AQP1 concentration in patients with clear cell or papillary cancer (n=32)
Number of subjects: 42
Study 20375178 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexcision urine ADFP concentration in patients with clear cell or papillary cancer (n=32)
Number of subjects: 42
Study 20375178 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnephrectomy urine AQP1 concentration in patients with clear cell or papillary cancer (n=25)
Number of subjects: 42